| 2025-11-06 |
详情>>
股本变动：
变动后总股本25211.82万股
|
| 2025-11-06 |
详情>>
业绩披露：
2025年三季报(累计)每股收益0.08美元,归母净利润1644.10万美元,同比去年增长1784.53%
|
| 2025-11-06 |
财报披露：
美东时间 2025-11-06 盘前发布财报
|
| 2025-10-01 |
详情>>
内部人交易：
Vaughan Brandt A.等共交易2笔
|
| 2025-07-31 |
详情>>
业绩披露：
2025年中报每股收益-0.04美元,归母净利润-817.8万美元,同比去年增长-92.56%
|
| 2025-05-08 |
详情>>
业绩披露：
2025年一季报每股收益-0.03美元,归母净利润-291.7万美元,同比去年增长-127.54%
|
| 2025-04-25 |
股东大会：
将于2025-06-12召开股东大会
会议内容 ▼▲
- 1.To vote upon the election of nine directors nominated by our Board of Directors to hold office until the 2026 Annual Meeting of Stockholders.
2.To approve the Third Amended and Restated 2016 Stock Incentive Plan.
3.To vote upon the approval, on an advisory basis, of the 2024 compensation of our named executive officers.
4.To vote upon the ratification of the selection of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025.
5.To conduct any other business properly brought before the Annual Meeting or any adjournment or postponement thereof.
|
| 2025-03-11 |
详情>>
业绩披露：
2022年年报每股收益0.16美元,归母净利润1991.90万美元,同比去年增长-5.31%
|
| 2025-03-11 |
详情>>
业绩披露：
2024年年报每股收益0.02美元,归母净利润225.90万美元,同比去年增长1585.82%
|
| 2024-11-07 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-0.01美元,归母净利润-97.6万美元,同比去年增长72.87%
|
| 2024-08-01 |
详情>>
业绩披露：
2023年中报每股收益-0.01美元,归母净利润-180.5万美元,同比去年增长-107.8%
|
| 2024-08-01 |
详情>>
业绩披露：
2024年中报每股收益-0.04美元,归母净利润-424.7万美元,同比去年增长-135.29%
|
| 2024-05-02 |
详情>>
业绩披露：
2024年一季报每股收益-0.01美元,归母净利润-128.2万美元,同比去年增长-192.3%
|
| 2024-04-29 |
股东大会：
将于2024-06-12召开股东大会
会议内容 ▼▲
- 1.To vote upon the election of nine directors nominated by our Board of Directors to hold office until the 2025 Annual Meeting of Stockholders.
2.To vote upon the approval, on an advisory basis, of the 2023 compensation of our named executive officers.
3.To vote upon the ratification of the selection of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024.
4.To conduct any other business properly brought before the Annual Meeting or any adjournment or postponement thereof.
|
| 2024-03-11 |
详情>>
业绩披露：
2023年年报每股收益0.00美元,归母净利润13.40万美元,同比去年增长-99.33%
|
| 2023-11-02 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-0.03美元,归母净利润-359.7万美元,同比去年增长-110.66%
|
| 2023-05-01 |
股东大会：
将于2023-06-14召开股东大会
会议内容 ▼▲
- 1.To vote upon the election of nine (9) directors nominated by our Board of Directors to hold office until the 2024 Annual Meeting of Stockholders.
2.To vote upon the approval of the 2023 Employee Stock Purchase Plan.
3.To vote upon the approval, on an advisory basis, of the 2022 compensation of our named executive officers.
4.To vote, on an advisory basis, on the frequency of future advisory votes on executive compensation.
5.To vote upon the ratification of the selection of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023.
6.To conduct any other business properly brought before the Annual Meeting or any adjournment or postponement thereof.
|
| 2022-05-02 |
股东大会：
将于2022-06-14召开股东大会
会议内容 ▼▲
- 1.To elect nine (9) directors nominated by our Board of Directors and named in the Proxy Statement to hold office until the 2023 Annual Meeting of Stockholders.
2.To approve the Second Amended and Restated 2016 Stock Incentive Plan.
3.To approve, on an advisory basis, the 2021 compensation of our named executive officers, as disclosed in this proxy statement.
4.To ratify the selection of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2022.
5.To conduct any other business properly brought before the Meeting or any adjournment or postponement thereof.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-08-03 |
复牌提示：
2021-08-03 09:34:11 停牌，复牌日期 2021-08-03 09:48:53
|
| 2021-05-10 |
股东大会：
将于2021-06-22召开股东大会
会议内容 ▼▲
- 1.To receive the consolidated financial statements of MDC Partners for the fiscal year ended December 31, 2020 and the auditors’ report thereon;
2.To elect the directors of MDC Partners;
3.To hold a non-binding advisory vote to approve executive compensation;
4.To appoint auditors and to authorize the Audit Committee to determine the auditors’ remuneration;
5.To transact such further and other business as may properly come before the Meeting or any adjournment or postponement thereof.
|
| 2021-05-10 |
股东大会：
将于2021-06-22召开股东大会
会议内容 ▼▲
- 1.the approval of the redomiciliation (the “Redomiciliation”) of MDC Canada from the federal jurisdiction of Canada to the State of Delaware (from and after the Redomiciliation, “MDC Delaware”) (the “Redomiciliation Proposal”);
2.the approval of each of the Proposed Transactions (as defined below), other than the Redomiciliation (the “Business Combination Proposal”), including the following:
2.1.Following the Redomiciliation, MDC Delaware will merge with one of its indirect wholly-owned subsidiaries (the “MDC Merger”), with MDC Delaware (from and after the MDC Merger, “OpCo”) surviving as a direct subsidiary of a newly-formed, NASDAQ-listed Delaware corporation (“New MDC”). Following the MDC Merger, OpCo will convert into a limited liability company (together with the MDC Merger, the “MDC Reorganization”) that will hold MDC’s operating assets.
2.2.At the closing of the Proposed Transactions, Stagwell will contribute (i) the issued and outstanding equity interest of Stagwell Marketing Group Holdings LLC (“SMGH”), the direct or indirect owner of the subsidiaries of Stagwell that own and operate a portfolio of marketing services companies (together with SMGH, the “Stagwell Subject Entities”), to OpCo in exchange for 216,250,000 common membership interests of OpCo (the “Stagwell OpCo Units”), and (ii) an aggregate amount of cash equal to $100 in to New MDC in exchange for 216,250,000 shares of a new Class C series of voting-only common stock of New MDC (the “Stagwell Issuance”) (the “Business Combination);
3.the granting of a proxy in relation to the common shares of MDC Delaware (the “MDC Delaware Common Shares”) and Series 6 convertible preference shares of MDC Delaware (the “MDC Delaware Series 6 Shares”) to be held by such MDC Canada Shareholder immediately following the consummation of the Redomiciliation, as applicable to each of MDC and The Stagwell Group LLC (each in such capacity, a “Proxyholder”) whereby each Proxyholder, acting singly, with respect to and on behalf of the holders of MDC Delaware Common Shares and the MDC Delaware Series 6 Shares that voted in favor of this proposal, may vote in favor of, or consent to, the approval and adoption of the Transaction Agreement and the Proposed Transactions, including the MDC Reorganization (collectively, the “MDC Delaware Consent”), which MDC Delaware Proxy (A) shall survive until the earlier of (1) the termination of the Transaction Agreement in accordance with its terms and (2) the effectiveness of the MDC Delaware Consent and (B) with respect to MDC, shall be granted conditional on MDC, in its capacity as Proxyholder, irrevocably committing to vote such MDC Delaware Common Shares and MDC Delaware Series 6 Shares to approve and adopt the Transaction Agreement and the Proposed Transactions, including the MDC Reorganization (the “MDC Delaware Proxy Proposal”);
4.in accordance with NASDAQ Listing Rule 5635, the approval of the issuance of the MDC Delaware Series 6 Shares, as described in Proposal 3 (the “Series 6 Supervoting Proposal”);
5.in accordance with NASDAQ Listing Rule 5635, the Stagwell Issuance, as described in Proposal 2 (the “Stagwell Issuance Proposal”);
6.the non-binding advisory approval of the compensation that may be paid or become payable to MDC’s named executive officers in connection with the Proposed Transactions (the “Compensation Proposal”).
|
| 2020-05-26 |
股东大会：
将于2020-06-25召开股东大会
会议内容 ▼▲
- 1.To receive the consolidated financial statements of MDC Partners for the fiscal year ended December 31, 2019 and the auditors’ report thereon;
2.To elect the directors of MDC Partners;
3.To hold a non-binding advisory vote to approve executive compensation;
4.To amend the 2016 Stock Incentive Plan;
5.To appoint auditors and to authorize the Audit Committee to determine the auditors’ remuneration;
6.To transact such further and other business as may properly come before the Meeting or any adjournment or postponement thereof.
|
| 2019-04-30 |
股东大会：
将于2019-06-04召开股东大会
会议内容 ▼▲
- 1.To receive the consolidated financial statements of MDC Partners for the fiscal year ended December 31, 2018 and the auditors’ report thereon;
2.To elect the directors of MDC Partners;
3.To appoint auditors and to authorize the Audit Committee to determine the auditors’ remuneration;
4.To hold a non-binding advisory vote to approve executive compensation;
5.To transact such further and other business as may properly come before the Meeting or any adjournment or postponement thereof.
|
| 2018-04-27 |
股东大会：
将于2018-06-06召开股东大会
会议内容 ▼▲
- 1.To elect the eight (8) director nominees of MDC Partners;
2.To appoint auditors and to authorize the Audit Committee to determine the auditors’ remuneration;
3.To hold a non-binding advisory vote to approve executive compensation;
4.To approve an amendment to the 2016 Stock Incentive Plan;
5.To transact such further and other business as may properly come before the Meeting or any adjournment thereof.
|
| 2017-04-27 |
股东大会：
将于2017-06-07召开股东大会
会议内容 ▼▲
- 1.To elect the seven (7) director nominees of MDC Partners;
2.To appoint auditors and to authorize the Audit Committee to determine the auditors’ remuneration;
3.To hold a non-binding advisory vote to approve executive compensation;
4.To hold a non-binding advisory vote on the frequency of future advisory votes on executive compensation;
5.To transact such further and other business as may properly come before the Meeting or any adjournment thereof.
|
| 2016-04-22 |
股东大会：
将于2016-06-01召开股东大会
会议内容 ▼▲
- 1.To elect the five (5) director nominees of MDC Partners;
2.To appoint auditors and to authorize the Audit Committee to determine the auditors’ remuneration;
3.To approve the Company’s 2016 Stock Incentive Plan;
4.To hold a non-binding advisory vote to approve executive compensation;
5.To transact such further and other business as may properly come before the Meeting or any adjournment thereof.
|